A citation-based method for searching scientific literature

Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 93







List of co-cited articles
624 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Amanda I Adler, Sharlene Ting, Ross Dent, Nick Latimer. Lancet Diabetes Endocrinol 2019
6
66

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
8
50


Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
23
17

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
40
10

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
4

Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.
Karen D Corbin, Kimberly A Driscoll, Richard E Pratley, Steven R Smith, David M Maahs, Elizabeth J Mayer-Davis. Endocr Rev 2018
91
4

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
161
4

Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States.
Stephanie N DuBose, Julia M Hermann, William V Tamborlane, Roy W Beck, Axel Dost, Linda A DiMeglio, Karl Otfried Schwab, Reinhard W Holl, Sabine E Hofer, David M Maahs. J Pediatr 2015
111
4

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
423
4


2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
565
4

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
60
6



Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Chantal Mathieu, Paresh Dandona, Andreas L Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus Florian Scheerer, Fredrik Thoren, Moshe Phillip. Diabetes Obes Metab 2020
16
25

Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Moshe Phillip, Tadej Battelino, Natasa Bratina, Klemen Dovc, Markus F Scheerer,[...]. Diabetes Obes Metab 2021
17
23


SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
John R Petrie. Lancet Diabetes Endocrinol 2017
8
37

SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
9
33

Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Frederik Staels, Carolien Moyson, Chantal Mathieu. Diabetes Obes Metab 2017
17
17

Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
556
3

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.
David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands. Diabetes Metab Syndr Obes 2015
15
20

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
L Rossetti, D Smith, G I Shulman, D Papachristou, R A DeFronzo. J Clin Invest 1987
700
3


Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Jenny E Blau, Viviana Bauman, Ellen M Conway, Paolo Piaggi, Mary F Walter, Elizabeth C Wright, Shanna Bernstein, Amber B Courville, Michael T Collins, Kristina I Rother,[...]. JCI Insight 2018
68
4

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
194
3

Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study.
G Riccardi, R Giacco, M Parillo, S Turco, A A Rivellese, M R Ventura, S Contadini, G Marra, M Monteduro, F Santeusanio,[...]. Diabet Med 1999
25
12

The mechanisms of action of metformin.
Graham Rena, D Grahame Hardie, Ewan R Pearson. Diabetologia 2017
882
3


Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
41
7

The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Suzanne M Strowig, Philip Raskin. Diabetes Care 2005
43
6

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
130
3




Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
S Sha, D Polidori, K Farrell, A Ghosh, J Natarajan, N Vaccaro, J Pinheiro, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2015
67
4


Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
188
3

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
3

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
162
3

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.
Michael J Bradburn, Jonathan J Deeks, Jesse A Berlin, A Russell Localio. Stat Med 2007
619
3

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. BMJ 2009
3

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
862
3

Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes.
Shiho Ayano-Takahara, Kaori Ikeda, Shimpei Fujimoto, Akihiro Hamasaki, Shin-Ichi Harashima, Kentaro Toyoda, Yoshihito Fujita, Kazuaki Nagashima, Daisuke Tanaka, Nobuya Inagaki. Diabetes Care 2015
20
15


Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Obes Metab 2018
46
6

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
224
3

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
599
3



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.